Bristol Cash And Equivalents from 2010 to 2024

BMY Stock  USD 53.25  0.70  1.33%   
Bristol Myers Cash And Equivalents yearly trend continues to be fairly stable with very little volatility. Cash And Equivalents will likely drop to about 10.5 B in 2024. During the period from 2010 to 2024, Bristol Myers Cash And Equivalents regression line of annual values had r-squared of  0.63 and arithmetic mean of  7,529,090,000. View All Fundamentals
 
Cash And Equivalents  
First Reported
2010-12-31
Previous Quarter
10.5 B
Current Value
10.5 B
Quarterly Volatility
3.9 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bristol Myers financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.2 B, Interest Expense of 1.2 B or Selling General Administrative of 8.4 B, as well as many exotic indicators such as Short Term Coverage Ratios of 4.01, Price Earnings Ratio of 19.89 or Price To Sales Ratio of 2.98. Bristol financial statements analysis is a perfect complement when working with Bristol Myers Valuation or Volatility modules.
  
This module can also supplement Bristol Myers' financial leverage analysis and stock options assessment as well as various Bristol Myers Technical models . Check out the analysis of Bristol Myers Correlation against competitors.

Latest Bristol Myers' Cash And Equivalents Growth Pattern

Below is the plot of the Cash And Equivalents of Bristol Myers Squibb over the last few years. It is Bristol Myers' Cash And Equivalents historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol Myers' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 9.12 B10 Years Trend
Slightly volatile
   Cash And Equivalents   
       Timeline  

Bristol Cash And Equivalents Regression Statistics

Arithmetic Mean7,529,090,000
Geometric Mean6,671,422,041
Coefficient Of Variation52.01
Mean Deviation3,436,108,000
Median5,421,000,000
Standard Deviation3,915,517,068
Sample Variance15331273.9T
Range10.3B
R-Value0.79
Mean Square Error6138612.4T
R-Squared0.63
Significance0.0004
Slope693,942,857
Total Sum of Squares214637834.7T

Bristol Cash And Equivalents History

202410.5 B
202310.5 B
20229.1 B
202114 B
202014.5 B
201912.3 B
20186.9 B

About Bristol Myers Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Bristol Myers income statement, its balance sheet, and the statement of cash flows. Bristol Myers investors use historical funamental indicators, such as Bristol Myers's Cash And Equivalents, to determine how well the company is positioned to perform in the future. Although Bristol Myers investors may use each financial statement separately, they are all related. The changes in Bristol Myers's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol Myers's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Bristol Myers Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Cash And Equivalents10.5 B10.5 B

Pair Trading with Bristol Myers

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bristol Stock

  0.69MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr

Moving against Bristol Stock

  0.7MMSI Merit Medical Systems Financial Report 24th of April 2024 PairCorr
  0.6MBIO Mustang Bio Report 3rd of April 2024 PairCorr
  0.56KA Kineta Inc Report 29th of March 2024 PairCorr
  0.56VBIV VBI Vaccines Financial Report 20th of May 2024 PairCorr
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol-Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Bristol-Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol Myers' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:
Check out the analysis of Bristol Myers Correlation against competitors.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Bristol Stock analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.09)
Dividend Share
2.31
Earnings Share
3.86
Revenue Per Share
21.753
Quarterly Revenue Growth
0.006
The market value of Bristol-Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.